SCYNEXIS, Inc. (SCYX) AI Stock Analysis
SCYX AI stock analysis summary
AI ResearchSCYNEXIS, Inc. is a biotechnology company focused on developing therapies for fungal infections, including its lead candidate ibrexafungerp. The company generated $20.6M in FY2025 revenue, up 449.9%, but holds a trailing twelve-month operating margin of -3308.5%. As of June 30, 2026, the business holds $52.1M in net cash, while its stock has declined 42.7% over the past year.
- Market cap
- $36.5M
- Revenue (TTM)
- $19.2M
- P/E
- — fwd 1.9x
- 1Y return
- -42.7% S&P 500 16.8%
- Avg. target
- $36.33 890.0% vs last close
Bull case
- SCYNEXIS maintains a solid liquidity cushion with net cash of $52.1M and a current ratio of 9.65 as of June 30, 2026.
- FY2025 revenue grew 449.9% to $20.6M, helping improve annual net income to -$8.6M from -$21.3M in FY2024.
- The analyst mean price target of $36.33 represents an 890.0% upside compared to the last close of $3.67.
Bear case
- Quarterly revenue fell 82.8% year-over-year in the period ended June 30, 2026, contributing to a trailing twelve-month operating margin of -3308.5%.
- Consensus estimates expect FY2026 revenue to contract sharply to $619,500, with an estimated EPS of -$2.91.
- Shareholder dilution has been substantial, evidenced by a 239.4% increase in the share count over five years.
What SCYNEXIS does
SCYNEXIS, Inc. is a biotechnology firm based in Jersey City, New Jersey, specializing in treatments for fungal infections in the United States. The company introduced BREXAFEMME (ibrexafungerp tablets) to treat vulvovaginal candidiasis (VVC). It is also developing its lead product candidate, ibrexafungerp, for oral and intravenous administration to target recurrent VVC, invasive aspergillosis, candidiasis, and refractory fungal infections. SCYNEXIS has strategic research collaborations with global partners including Merck Sharp & Dohme Corp., Hansoh Health Technology Co., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to advance and commercialize ibrexafungerp across multiple therapeutic applications.
Growth and profitability
Revenue has shown notable volatility, reporting $13.2M in FY2021 and $5.1M in FY2022 before jumping to $140.1M in FY2023. Revenue subsequently dropped to $3.7M in FY2024 before increasing to $20.6M in FY2025. Gross margin was 100.0% in FY2025, while operating margin improved to -78.0% compared to -990.8% in FY2024. Net income for FY2025 was -$8.6M with EPS of $0.54, up from a net loss of -$21.3M and EPS of -$2.89 in FY2024. For the trailing twelve months ended June 30, 2026, revenue was $19.2M with EPS of -$0.89, as quarterly revenue fell 82.8% year-over-year.
Balance sheet and cash flow
As of June 30, 2026, SCYNEXIS had $54.1M in cash and short-term investments against $1.9M in total debt, leaving net cash of $52.1M. Shareholders' equity was $66.9M and total assets were $75.0M. The company reported a current ratio of 9.65 and a debt-to-equity ratio of 0.03. In FY2025, operating cash flow was -$5.3M, equal to free cash flow of -$5.3M. Over five years, the company's share count increased by 239.4%.
Valuation and performance
SCYNEXIS has a market capitalization of $36.5M and an enterprise value of -$6.7M. The stock trades at a price-to-book ratio of 0.7x and a price-to-sales ratio of 1.9x, below the median of its US-listed Healthcare peers of 4.1x. Its forward P/E is 1.9x versus the peer median of 17.3x, and its EV/EBITDA multiple is 0.1x compared to the peer median of 12.0x. Over the past year, the stock fell 42.7% and is down 27.5% year-to-date, lagging the S&P 500 (SPY) one-year return of 16.8%.
What analysts expect
Analyst ratings include 2 Strong Buy ratings, 1 Buy rating, and zero Hold or Sell recommendations. The mean price target is $36.33, compared to the last close of $3.67, representing a target vs last close of 890.0%. For the fiscal year ending December 31, 2026, consensus estimates project an EPS of -$2.91 on revenue of $619,500. SCYNEXIS has beaten EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 4, 2026.
Key risks and what to watch
- Free cash flow has been negative in four of the last five fiscal years, including -$5.3M in FY2025.
- Historical annual revenues have been highly inconsistent, dropping 97.3% in FY2024 to $3.7M after reaching $140.1M in FY2023.
- The stock price of $3.67 trades 34.6% below its 200-day moving average and near its 52-week low of $3.53.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this SCYX AI stock analysis
This page is an AI-written research summary of SCYNEXIS, Inc. (SCYX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: SCYX income statement, SCYX balance sheet, SCYX key metrics, SCYX analyst forecast, SCYX chart. See the SCYX stock overview for the latest quote and news.
SCYX AI stock analysis FAQ
What is SCYNEXIS's cash and debt position?
As of June 30, 2026, SCYNEXIS held $54.1M in cash and short-term investments and $1.9M in total debt, resulting in net cash of $52.1M.
What are analysts forecasting for SCYX in FY2026 and FY2027?
For FY2026, analysts project revenue of $619,500 and an EPS of -$2.91. For FY2027, 2 analysts estimate revenue of $6.7M and an EPS of -$2.31.
Does SCYNEXIS pay a dividend?
SCYNEXIS does not pay a dividend.
How has SCYX stock performed relative to the market?
Over the past year, SCYX shares fell 42.7% and are down 27.5% year-to-date, trailing the S&P 500 (SPY) one-year return of 16.8%.